What side effects do Praluent and Repatha have in common?
Praluent (alirocumab) and Repatha (evolocumab) are both PCSK9 inhibitors given as injections. Because they target the same pathway, many side effects overlap, especially injection-site reactions. Patients also report flu-like or cold-like symptoms and muscle-related complaints (such as pain or cramps) with both drugs, though the exact mix of events can differ by study and by patient.
How do the side effect profiles of Praluent vs Repatha differ?
Both drugs can cause injection-site reactions, but the pattern of other reported adverse events can vary between trials and between the prescribing labels for each product. When comparing “Praluent vs Repatha side effects,” the most practical approach is to compare their labeled adverse events and frequency in large trials, since that determines what clinicians most often see.
If you tell me whether you’re comparing:
- the prescribing-label “most common” side effects, or
- serious side effects patients worry about (like neurologic symptoms, allergic reactions, or muscle problems),
I can tailor the comparison more precisely.
What injection-site side effects should patients watch for?
For both Praluent and Repatha, common injection-site effects include redness, pain, swelling, itching, or bruising where the shot is given. These are usually mild but can be frequent enough that patients adjust injection technique, rotate sites, or use supportive measures.
What other side effects are patients most concerned about?
Patients commonly ask about:
- Muscle symptoms (for example, muscle pain or cramps), since these are commonly discussed with cholesterol-lowering therapies more broadly.
- Allergic reactions, including hypersensitivity symptoms after injection (rare but important).
- General viral-like symptoms (such as upper respiratory symptoms).
The key practical point is that any severe rash, trouble breathing, or swelling after an injection should be treated as urgent and reported immediately.
Do Praluent or Repatha increase the risk of diabetes, liver problems, or kidney issues?
For PCSK9 inhibitors, the questions you’d typically see are about whether they meaningfully change risks like diabetes, liver enzymes, or kidney outcomes. The safest way to answer is to use the most up-to-date prescribing information for each product, because risk signals can differ by population and follow-up duration.
What side effects are more likely if you also take a statin?
Many real-world patients take a PCSK9 inhibitor on top of a statin or other lipid therapy. That matters because muscle complaints can be hard to attribute to one drug. If you’re already on a statin and develop new muscle pain, clinicians usually evaluate whether it’s timing-related, assess severity, and check labs as appropriate.
When should you contact a doctor about side effects?
Contact a clinician promptly for:
- Severe or worsening injection-site reactions
- Signs of allergy (hives, facial swelling, wheezing, or breathing difficulty)
- New, severe muscle pain or weakness
- Any symptoms that feel unusual or rapidly worsening
Quick “which one tends to be better tolerated?”
Most patients tolerate either option, and differences often come down to individual sensitivity and the specific side effects you’ve had before. If you had injection-site reactions or other adverse effects on one, switching within the class can sometimes help, but it can also reproduce similar reactions.
Source
DrugPatentWatch.com tracks drug and patent information, but it is not a primary clinical-safety source for side-effect frequencies. If you want, I can still use it for sourcing where it references product details—tell me which country’s label you’re using (US/EU/UK) and whether you’re comparing the “common adverse reactions” section or serious events.
Sources:
1. DrugPatentWatch.com